Apimeds Pharmaceuticals US, Inc
Apimeds Pharmaceuticals US, Inc (APUS) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
apus · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Apimeds Pharmaceuticals US, Inc (APUS) measures how much investors pay for each dollar of the company's trailing earnings. APUS's current PE ratio of N/A is calculated by dividing its stock price of $1.28 by its TTM earnings per share of -$2.62.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2021 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Apimeds Pharmaceuticals US, IncYou APUS | $2M | N/A | — | -$2.62 |
 AN2 Therapeutics, Inc. ANTX | $105M | N/A | — | -$1.16 |
 IGC Pharma, Inc. IGC | $30M | N/A | — | -$0.07 |
 MIRA Pharmaceuticals, Inc. MIRA | $42M | N/A | — | -$0.44 |
 Milestone Scientific Inc. MLSS | $34M | N/A | — | -$0.07 |
 Myomo, Inc. MYO | $49M | N/A | — | -$0.37 |
 NextCure, Inc. NXTC | $7M | N/A | — | -$19.65 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-0.55 | — | |
2024-12-31 FY2024 | — | $-1.21 | — | |
2023-12-31 FY2023 | — | $-0.67 | — | |
2022-12-31 FY2022 | — | $-0.58 | — | |
2021-12-31 FY2021 | — | $-0.89 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Apimeds Pharmaceuticals US, Inc (APUS) measures how much investors pay for each dollar of the company's trailing earnings. APUS's current PE ratio of N/A is calculated by dividing its stock price of $1.28 by its TTM earnings per share of -$2.62.
Frequently asked questions
APUS pe ratio · 6 questionsAPUS's current PE ratio is N/A as of 2026-06-09, based on a stock price of $1.28 and TTM EPS of -$2.62. Data sourced from Financial Modeling Prep via APUS's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Apimeds Pharmaceuticals US, Inc SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09